INVA earnings analysis
What we found in INVA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Innoviva reported Q1 2026 revenue of $98.0 million, showing an 11% growth year-over-year, alongside a strong diluted EPS of $2.52, largely buoyed by a robust increase in net product sales. The company highlights significant gains in its operating income and strong performance within specific segments, particularly XACDURO® and GIAPREZA®.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- 11% Revenue Growth Year-over-Year
- Total revenue for Q1 2026 reached $98.0 million, up from $88.6 million in Q1 2025.
- Strong Diluted EPS Performance
- Diluted EPS was reported at $2.52, a substantial increase from a net loss of $0.74 in Q1 2025.
- Significant Growth in Net Product Sales
- Net product sales grew to $41.4 million, representing a 37% increase from $30.3 million in the same quarter of the prior year.
- Healthy Balance Sheet Position
- Cash and cash equivalents stood at $603.1 million, showcasing a solid liquidity position.
- Share Repurchase Program Confidence
- Innoviva repurchased 971,066 shares for $20.4 million, reflecting strong confidence in the company’s intrinsic value.
- Favorable Fair Value Changes in Investments
- The changes in fair value of equity investments resulted in a net gain of $191.2 million, predominantly from Armata.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Dependency on Royalty Revenue
- Royalty revenue from GSK decreased to $55.2 million, down 5% from $57.8 million the previous year due to sales pressures.
- Increase in Operating Expenses
- SG&A expenses rose to $32.4 million in Q1 2026 from $27.5 million in Q1 2025, driven by promotional activities.
- High Interest Expense Obligations
- Interest expenses increased to $5.4 million in Q1 2026, compared to $4.7 million in Q1 2025, impacting profitability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $2.52
- Segment
- Royalty Revenue: $58.6M
- Segment
- Net Product Sales: $41.4M
What they said about what is next.
Management maintains FY 2026 revenue guidance between $430 million and $460 million.
The filing reads better than the one before it.
What came before.
- 10-K · February 25, 2026
- Innoviva describes a strategic shift from a pure-play royalties business toward a diversified biopharmaceutical company focused on (1) maximizing respiratory royalties from GSK, (2) growing its Innoviva Specialty…
- 10-Q · November 5, 2025
- Innoviva reported Q3 2025 revenue of $107,800 (thousands) and diluted EPS of $1.08, driven by strong net product sales and large realized/unrealized investment fair value gains. Operating performance showed margin…
- 10-Q · August 6, 2025
- Innoviva, Inc. reported a strong Q2 2025 with revenues of $100.283 million, slightly up from the $99.898 million reported a year ago, marking a 0.4% increase. Notably, diluted EPS surged to $0.77, significantly…
- 10-K · February 26, 2025
- Innoviva positions itself as a royalties manager (respiratory royalties with GSK) plus an operating critical care & infectious disease platform (IST) anchored by four commercial products and a pipeline. The filing…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing INVA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever